Korean Diabetes J.  2008 Apr;32(2):171-172. 10.4093/kdj.2008.32.2.171.

Prevalence and Clinical Characteristics of Aspirin Resistance in the Patients with Type 2 Diabetes

• Kim SY

• KMID: 2222514
• DOI: http://doi.org/10.4093/kdj.2008.32.2.171

Abstract

No abstract available.

MeSH Terms

Aspirin
Humans
Prevalence
Aspirin

Reference

1. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J. 2007. 28:1925–1927.

2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy fot prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002. 324:71–86.

3. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project(PPP) trial. Diabetes Care. 2003. 26:3264–3272.

4. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005. 42:99–103.

5. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Gildfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006. 97:567–570.

7. Watala C, Boncler M, Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep. 2005. 57(Suppl):42–58.